

Navigating Haemodynamics see what we see

Introducing TrueVue™ PressureWave

TrueVue PressureWave™ utilises the most stable and extensively researched Pulse Pressure Wave Algorithm (PPWA) currently available, which is the algorithm proposed by Liljestrand & Zander. Clinical validations of this algorithm have been published¹ in peer reviewed journals. Deltex Medical has also performed its own extensive evaluations of its performance in a wide range of clinical situations.

The Liljestrand and Zander algorithm has been shown to be superior to eight other investigational algorithms and MAP as a quantitative estimator of CO^{2,6}. Even so all PPWA algorithms have limitations particularly in periods of haemodynamic instability. TrueVue allows the user to switch between modes of use so that the clinician can use the proven TrueVue Doppler technology to guide intervention; to calibrate the TrueVue PressureWave for continuous monitoring in periods of stability or when it is anticipated that Doppler flow measurement may be temporarily unavailable (e.g. fully conscious patients not tolerating the probe, oesophagectomy, periods of diathermy).

Easiest calibration of PPWA

The TrueVue PressureWave uses the proven Doppler technology to control both its Flow Monitoring Mode and the calibration of the PPWA algorithm for its Pressure Monitoring Mode estimation of cardiac output. Uncalibrated PPWA algorithms have been shown to be prone to drift due to changes in vascular tone, arterial compliance and the consequent arterial blood pressure variation. These changes have been reported to be clinically significant. Leaders in the field of PPWA technology have also strongly recommended calibration before major clinical decisions are taken³.

Recalibration may therefore be even more important than initial calibration. The inability to recalibrate easily before intervention has resulted in limitations in the use and precision of PPWA. TrueVue PressureWave solves the PPWA calibration problem at the highest level of precision in a matter of seconds. Simply focus the TrueVue Doppler signal and calibrate the PPWA algorithm at the touch of a button. Studies of PPWA devices recommend that in critically ill patients the device should be recalibrated at least every four hours and that recalibration should be performed before major clinical decisions are made^{4,5}.

The TrueVue PressureWave follows this clinical advice but now provides the capability to recalibrate at any moment using the quick, easy, minimally invasive and clinically proven TrueVue Doppler method at no additional cost.

References

1. **Liljestrand G, Zander E:** Vergleichen die bestimmungen des minutenvolumens des herzens beim menschen mittels der stichoxydulmethode und durch blutdruckmessung. Ztschr ges exper med 1928; (59):105-122
2. **Sun, J.X:** Cardiac Output Estimation using Arterial Blood Pressure Waveforms. Thesis for Master of Engineering in Electrical Engineering and Computer Science. Massachusetts Institute of Technology Sept. 2006
3. **Linton, N.W.F. & Linton, R.A.F:** Estimation of changes in cardiac output from the arterial blood pressure waveform in the upper limb. British Journal of Anaesthesia 2001; 86 (4): pp 486-496
4. **Cecconi, M., et al:** Lithium dilution cardiac output measurement in the critically ill patient: determination of precision of the technique. Intensive Care Med. 2009; 35 (3): pp 498-504
5. **Cecconi, M., et al:** A prospective study to evaluate the accuracy of pulse power analysis to monitor cardiac output in critically ill patients. BMC Anesthesiology 2008, 8:3 <http://www.biomedcentral.com/1471-2253/8/3>
6. **Sun, J.X., et al:** The cardiac output from blood pressure algorithms trial. Crit Care Med 2009; 37(1): pp 72-80.


One TrueVue™ SYSTEM three best in class technologies - right technology, right monitoring, right intervention for the right patient.

“ Myocardial injury is the leading cause of postoperative death and the third leading cause of death overall in the United States ”

Cleveland Clinic Researchers (Clinical Anesthesiology 2016)

Monitoring is the key to informed risk assessment to avoid covert cardiac injury.

Your patients, your choices



One Platform Three Technologies

A world first from the world's most innovative haemodynamic monitoring company.

- Complete Haemodynamic Platform
- Best in Class Technologies
- Real Time Biomarkers.

TrueVue™ System, the first to combine three 'Best in Class' technologies, into one platform.

Clinicians can now choose the most appropriate technology for each patient. Newborn to adult, awake or anaesthetised, across all hospital settings.

Choose expert support

Expert clinical support and training

- bedside, classroom and online
- Deltex Medical App.



Business case and implementation support

- modern perioperative patient safety, quality improvement projects and enhanced recovery roll-out.

deltexmedical.education/en

Deltex Medical Limited

Terminus Road | Chichester | PO19 8TX | United Kingdom

Enquiries.....+44 (0)1243 774837

Email.....sales@deltexmedical.com

Online.....www.deltexmedical.com

Deltex

see what we see

Social Media.....Follow us

Deltex App.....Available from



Search Deltex

eLearning.....deltexmedical.education/en